Bio-Techne discloses merger proxy lawsuit, supplements disclosures

BIO-TECHNE Corp

Shareholder lawsuit filed Sept 9, 2026 in Minnesota court alleges proxy omitted material info; seeks to block merger vote.
Bio-Techne denies merit, voluntarily supplements proxy; says disclosures comply with law.
Supplement reveals Goldman Sachs implied present value of $58-$72/share (DCF) and $45-$74/share (multiple-based).
Also discloses no post-closing employment discussions with merger parties from July 2025 to agreement execution.
Special meeting for Merck KGaA merger vote remains scheduled for Sept 23, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.